| Literature DB >> 32952230 |
Juan Fernando Aristizábal1, Héctor Rios2, Diego Rey3, María Antonia Álvarez3, Beatriz Parra4, Mario Ortiz5.
Abstract
AIM: We aimed to evaluate the correlation between the polymorphism of the interleukin 1-Beta (IL1-β, +3954 C>T) and tooth movement, in a group of Colombian patients undergoing surgically accelerated orthodontic tooth movement.Entities:
Keywords: Cytokines; Interleukin-1beta; Orthodontic Tooth Movement; Single Nucleotide Polymorphism
Mesh:
Substances:
Year: 2020 PMID: 32952230 PMCID: PMC7467119 DOI: 10.25100/cm.v51i1.4141
Source DB: PubMed Journal: Colomb Med (Cali) ISSN: 0120-8322
Distribution of sex and age variables of study participants according to the intervention group. p-values correspond to Kruskal-Wallis test. Values in bold indicate significant differences.
| Group 1 (n=9) | Group 2 (n=10) | Group 3 (n=10) | Group 4 (n=8) | Total (n=37) |
| |
|---|---|---|---|---|---|---|
| Age (years±sd) | 23.77±5.71 | 21.10±3.84 | 30.10±6.83 | 27±4.40 | 25.45 ±6.23 | 0.01 |
| Gender (n (%))† | ||||||
| Female (n) | 3 (33.33) | 3 (30) | 2 (20) | 3 (29.73) | 11 (29.73) | 0.93 |
| Male (n) | 6 (66.66) | 7 (70) | 8 (80) | 5 (70.27) | 26 (70.27) | |
| SNP (n(%))† | 4 (40) | 3 (30) | 1 (10) | 2 (20) | 10 (100) | 0.42 |
Fisher's exact test
Alignment and total treatment time according to the intervention group.
| Variables | Group 1 (n=9)* | Group 2 (n=10)* | Group 3 (n=10)* | Group 4 (n=8)* | Total (n=37)* | |
|---|---|---|---|---|---|---|
| Alignment phase (days) | ||||||
| Upper Arch† | 179.2±27.3 | 98.8±56.7 | 137.4±130.2 | 156±68.5 | 141.2±83.9 |
|
| Lower Arch† | 206.7 ±38.4 | 146.7±102.2 | 165.3±67.2 | 179±69.1 | 409.6±120.3 | 0.25 |
| Total Treatment Time (days) ‡ | 475.3±98.3 | 433.0±152.3 | 373.9±115.8 | 351.1±65.4 | 409.6±120.3 | 0.12 |
| Minor Treatment Time
| 8.0 (23.5) | 9.0 (26.5) | 9.0 (26.5) | 8.0 (23.5) | 34.0 (100.0) | 1.00 |
Mean ± SD
Kruskal-Wallis test (1vs2, 1vs3, 2vs4 Mann Whitney pairwise comparison), ‡ANOVA test, §Chi-Squared test. Values in bold indicate significant differences.
Figure 1Allelic discrimination analysis of SNP +3954 C> T in the interleukin 1 beta gene (IL-1β) shown as scatterplot of Allele 1 (nucleotide C) in x-axis versus Allele 2 (nucleotide T) in y-axis. Dot colored blue (y-axis) corresponds to the positive control for the Allele 2 homozygous (T/T), dots colored red (x-axis) represent 19 homozygous subjects for the allele 1 (C/C) and the positive control , and dots colored green in the diagonal correspond to 11 subjects expressing the SNP +3954 C> T in heterozygous manner (C/T).
Alignment time and total treatment time according to the presence of the SNP.
| Variables | Present (n=10) | Absent (n=27) | Total (n=37) |
|---|---|---|---|
| Alignment phase (days) | |||
| Upper Arch | 179.2±27.3 | 98.8±56.7 | 141.2±83.9 |
| Lower Arch | 206.7 ±38.4 | 146.7±102.2 | 409.6±120.3 |
| Total Treatment Time (days) | 475.3±98.3 | 433±152.3 | 409.6±120.3 |
| Minor Treatment Time
| 8.0 (76.5) | 26.0 (23.5) | 34.0 (100.0) |
*Mean ± sd
Incidence rates for total treatment time and presence of polymorphism.
| Group | Time (days) | n | TI | TI - 95% IC | RTI | RTI - 95% IC |
|---|---|---|---|---|---|---|
| 1 | 4,278 | 9 | 2.1 | 1.1 - 4.0 | 1 | |
| 2 | 4,330 | 10 | 2.3 | 1.2 - 4.3 | 1.1 | 0.4 - 3.0 |
| 3 | 3,739 | 10 | 2.7 | 1.4 - 4.9 | 1.3 | 0.5 - 3.5 |
| 4 | 2,809 | 8 | 2.8 | 1.4 - 5.7 | 1.4 | 0.5 - 3.9 |
| Without SNP | 1,054 | 27 | 2.5 | 1.8 - 3.7 | 1 | |
| With SNP | 4,613 | 10 | 2.2 | 1.2 - 4.0 | 0.9 | 0.4 - 1.8 |
n: number of treatments completed.
TI: Incidence rate x 1000 people-day.
RTI: Reason for incidence rates.
95% IC: 95% confidence interval
Ratio of proportional hazards for total treatment time, upper arch and lower arch alignment
| Variable | Groups | HR | SE | z | p(z) | 95% CI |
|---|---|---|---|---|---|---|
| Total treatment | SNP | 0.6 | 0.3 | -1.2 | 0.24 | 0.3-1.4 |
| Group | 1.4 | 0.2 | 1.8 | 0.08 | 0.9-1.9 | |
| SNP*Group 1 | 0.6 | 0.2 | -1.3 | 0.18 | 0.2-1.3 | |
| SNP*Group 2 | 0.9 | 0.5 | -0.1 | 0.89 | 0.4-2.4 | |
| SNP*Group 3 | 1.4 | 0.7 | 0.6 | 0.55 | 0.5-3.8 | |
| SNP*Group 4 | 2.5 | 1.3 | 1.8 | 0.07 | 0.9-6.9 | |
| Upper arch | SNP | 1.3 | 0.5 | 0.7 | 0.51 | 0.6-2.9 |
| Group | 1.0 | 0.2 | 0.0 | 0.97 | 0.8-1.3 | |
| SNP*Group 1 | 1.5 | 0.7 | 1.0 | 0.34 | 0.7-3.5 | |
| SNP*Group 2 | 2.8 | 1.3 | 2.2 | 0.03 | 1.1-7.2 | |
| SNP*Group 3 | 2.0 | 1.1 | 1.2 | 0.22 | 0.7-5.7 | |
| SNP*Group 4 | 1.1 | 0.6 | 0.2 | 0.83 | 0.4-3.2 | |
| Lower arch | SNP | 0.9 | 0.4 | -0.3 | 0.73 | 0.4-1.9 |
| Group | 1.0 | 0.2 | 0.3 | 0.79 | 0.8-1.4 | |
| SNP*Group 1 | 0.8 | 0.4 | -0.4 | 0.69 | 0.4-1.9 | |
| SNP*Group 2 | 1.5 | 0.7 | 0.8 | 0.40 | 0.6-3.8 | |
| SNP*Group 3 | 1.3 | 0.6 | 0.5 | 0.62 | 0.5-3.3 | |
| SNP*Group 4 | 1.2 | 0.6 | 0.3 | 0.78 | 0.4-3.2 |
HR: Hazard ratio
SE: Standard Error
95% CI: 95% confidence interval
We considered the presence of the SNP and the group as separated variables, and the combined effects of SNP and groups (SNP*Group).
Figure 2Estimation of the risk function by Kaplan Meier according to the presence / absence of polymorphism for the variables (A) total treatment time, (B) upper arch alignment and (C) lower arch alignment. Blue line: without SNP, Red line: with SNP.
Incidence rates of upper arch alignment by treatment and presence of polymorphism
| Person-time | Aligned (n) | IR | IR - CI 95% | RIR | RIR - CI 95% |
| |
|---|---|---|---|---|---|---|---|
| Group | |||||||
| 1 | 1,613 | 9 | 5.58 | 2.90-10.72 | 1 | ||
| 2 | 988 | 10 | 10.12 | 5.45-18.81 | 1.81 | 0.66-5.05 | 0.20 |
| 3 | 1,374 | 10 | 7.28 | 3.92-13.53 | 1.30 | 0.48-3.63 | 0.57 |
| 4 | 1,248 | 8 | 6.41 | 3.21-12.82 | 1.15 | 0. 39-3.35 | 0.78 |
| SNP | |||||||
| Without SNP | 3,915 | 27 | 6.90 | 4.73-10.06 | 1 | ||
| With SNP | 1,308 | 10 | 7.65 | 4.11-14.21 | 1.11 | 0.48-2.36 | 0.76 |
IR: Incidence rate x 1,000 people-day,
RIR: Reason for incidence rates.
95%, CI: 95% confidence interval
Accumulated incidence rates of lower arch alignment by treatment and presence of polymorphism.
| Person-time | Aligned failures (n) | IR rate | IR - CI 95% | RIR | RIR - CI 95% |
| |
|---|---|---|---|---|---|---|---|
| Group | |||||||
| 1 | 1,860 | 9 | 4.84 | 2.52-9.30 | 1 | ||
| 2 | 1,467 | 10 | 6.82 | 3.67-12.67 | 1.41 | 0.51-3.92 | 0.46 |
| 3 | 1,653 | 10 | 6.05 | 3.26-11.24 | 1.25 | 0.46-3.48 | 0.63 |
| 4 | 1,253 | 7 | 5.59 | 2.67-11.72 | 1.15 | 0.37-3.48 | 0.77 |
| SNP | |||||||
| Without SNP | 4,350 | 26 | 5.98 | 4.07-8.78 | 1 | ||
| With SNP | 1,883 | 10 | 5.31 | 2.86-9.87 | 0.89 | 0.38-1.90 | 0.77 |
IR: Incidence rate x 1,000 people-day,
RIR: Reason for incidence rates.
95%, CI: 95% confidence interval
Distribución de las variables de sexo y edad de los participantes del estudio según el grupo de intervención. Los valores p corresponden a la prueba de Kruskal-Wallis. Los valores en negrilla indican diferencias significativas.
| Grupo 1 (n=9) | Grupo 2 (n=10) | Grupo 3 (n=10) | Grupo 4 (n=8) | Total (n=37) | ||
|---|---|---|---|---|---|---|
| Edad (años±SD) | 23.77±5.71 | 21.10±3.84 | 30.10±6.83 | 27±4.40 | 25.45 ±6.23 | 0.01 |
| Sexo (n (%))† | ||||||
| Femenino (n) | 3 (33.33) | 3 (30) | 2 (20) | 3 (29.73) | 11 (29.73) | 0.93 |
| Masculino (n) | 6 (66.66) | 7 (70) | 8 (80) | 5 (70.27) | 26 (70.27) | |
| SNP (n(%))† | 4 (40) | 3 (30) | 1 (10) | 2 (20) | 10 (100) | 0.42 |
†Prueba exacta de Fisher
Alineación y tiempo total de tratamiento según el grupo de intervención.
| Variables | Grupo 1 (n=9)* | Grupo 2 (n=10)* | Grupo 3 (n=10)* | Grupo 4 (n=8)* | Total (n=37)* | |
|---|---|---|---|---|---|---|
| Fase de alineación (días) | ||||||
| Arco superior† | 179.2±27.3 | 98.8±56.7 | 137.4±130.2 | 156±68.5 | 141.2±83.9 | |
| Arco inferior† | 206.7 ±38.4 | 146.7±102.2 | 165.3±67.2 | 179±69.1 | 409.6±120.3 | 0.25 |
| Tiempo Total de Tratamiento (días) ‡ | 475.3±98.3 | 433.0±152.3 | 373.9±115.8 | 351.1±65.4 | 409.6±120.3 | 0.12 |
| Tiempo de Tratamiento Menor | 8 (23.5) | 9 (26.5) | 9 (26.5) | 8 (23.5) | 34 (100.0) | 1.00 |
* Media ± Desviación estandard
†Prueba Kruskal-Wallis (1vs2, 1vs3, 2vs4 Comparación de pares de Mann Whitney),
‡Prueba ANOVA, §Prueba Chi-Cuadrado. Los valores en negrilla indican diferencias significativas.
Figura 1Análisis de discriminación alélica de SNP +3954 C> T en el gen beta de interleucina 1 (IL-1β) mostrado como diagrama de dispersión del alelo 1 (nucleótido C) en el eje x versus alelo 2 (nucleótido T) en el eje y. Los puntos de color azul (eje y) corresponden al control positivo para el alelo 2 homocigoto (T / T), los puntos de color rojo (eje x) representan 19 sujetos homocigotos para el alelo 1 (C / C) y el control positivo. Los puntos de color verde en la diagonal corresponden a 11 sujetos que expresan el SNP +3954 C> T de manera heterocigótica (C / T).
Tiempo de alineación y tiempo total de tratamiento de acuerdo a la presencia del SNP.
| Variables | Presente (n= 10)* | Ausente (n= 27)* | Total (n= 37)* |
|---|---|---|---|
| Fase de alineación (días) | |||
| Arco superior | 179.2±27.3 | 98.8±56.7 | 141.2±83.9 |
| Arco inferior | 206.7 ±38.4 | 146.7±102.2 | 409.6±120.3 |
| Tiempo Total de Tratamiento (días) | 475.3±98.3 | 433±152.3 | 409.6±120.3 |
| Tiempo de Tratamiento Menor | 8 (76.5) | 26 (23.5) | 34 (100.0) |
* Media ± SD
Tasas de incidencia para el tiempo total de tratamiento y la presencia de polimorfismo.
| Grupo | Tiempo (días) | n | TI | TI - 95% IC | RTI | RTI - 95% IC |
|---|---|---|---|---|---|---|
| 1 | 4,278 | 9 | 2.1 | 1.1 - 4.0 | 1 | |
| 2 | 4,330 | 10 | 2.3 | 1.2 - 4.3 | 1.1 | 0.4 - 3.0 |
| 3 | 3,739 | 10 | 2.7 | 1.4 - 4.9 | 1.3 | 0.5 - 3.5 |
| 4 | 2,809 | 8 | 2.8 | 1.4 - 5.7 | 1.4 | 0.5 - 3.9 |
| Sin SNP | 1,054 | 27 | 2.5 | 1.8 - 3.7 | 1 | |
| Con SNP | 4,613 | 10 | 2.2 | 1.2 - 4.0 | 0.9 | 0.4 - 1.8 |
n: Cantidad de tratamientos completados.
TI: Tasa de incidencia x 1,000 personas-día.
RTI: Razón de las tasas de incidencia. 95%IC: 95% intervalo de confianza
Razón de riesgos proporcionales para el tiempo total de tratamiento, la alineación del arco superior y el arco inferior.
| Variable | Grupo | CR | SE | z | p(z) | IC 95% |
|---|---|---|---|---|---|---|
| Tratamiento completo | SNP | 0.6 | 0.3 | -1.2 | 0.24 | 0.3-1.4 |
| Grupo | 1.4 | 0.2 | 1.8 | 0.08 | 0.9-1.9 | |
| SNP*Grupo 1 | 0.6 | 0.2 | -1.3 | 0.18 | 0.2-1.3 | |
| SNP*Grupo 2 | 0.9 | 0.5 | -0.1 | 0.89 | 0.4-2.4 | |
| SNP*Grupo 3 | 1.4 | 0.7 | 0.6 | 0.55 | 0.5-3.8 | |
| SNP*Grupo 4 | 2.5 | 1.3 | 1.8 | 0.07 | 0.9-6.9 | |
| Arco superior | SNP | 1.3 | 0.5 | 0.7 | 0.51 | 0.6-2.9 |
| Grupo | 1.0 | 0.2 | 0.0 | 0.97 | 0.8-1.3 | |
| SNP*Grupo 1 | 1.5 | 0.7 | 1.0 | 0.34 | 0.7-3.5 | |
| SNP*Grupo 2 | 2.8 | 1.3 | 2.2 | 0.03 | 1.1-7.2 | |
| SNP*Grupo 3 | 2.0 | 1.1 | 1.2 | 0.22 | 0.7-5.7 | |
| SNP*Grupo 4 | 1.1 | 0.6 | 0.2 | 0.83 | 0.4-3.2 | |
| Arco inferior | SNP | 0.9 | 0.4 | -0.3 | 0.73 | 0.4-1.9 |
| Grupo | 1.0 | 0.2 | 0.3 | 0.79 | 0.8-1.4 | |
| SNP*Grupo 1 | 0.8 | 0.4 | -0.4 | 0.69 | 0.4-1.9 | |
| SNP*Grupo 2 | 1.5 | 0.7 | 0.8 | 0.40 | 0.6-3.8 | |
| SNP*Grupo 3 | 1.3 | 0.6 | 0.5 | 0.62 | 0.5-3.3 | |
| SNP*Grupo 4 | 1.2 | 0.6 | 0.3 | 0.78 | 0.4-3.2 |
CR: Cociente de riesgo,
EE: Error estándar,
IC 95%: 95% intervalo de confianza.
Se consideró la presencia del SNP y el grupo como variables separadas, y los efectos combinados del SNP y los grupos. (SNP*Grupo).
Figura 2Estimación de la función de riesgo de Kaplan Meier según la presencia / ausencia de polimorfismo para las variables (A) tiempo total de tratamiento, (B) alineación del arco superior y (C) alineación del arco inferior. Línea azul: sin SNP, Línea roja: con SNP.
Tasas de incidencia de alineación del arco superior por tratamiento y presencia de polimorfismo
| Persona-tiempo | Alineado (n) | TI | TI - IC 95% | RTI | RTI - IC 95% | ||
|---|---|---|---|---|---|---|---|
| Grupo | |||||||
| 1 | 1,613 | 9 | 5.58 | 2.90-10.72 | 1 | ||
| 2 | 988 | 10 | 10.12 | 5.45-18.81 | 1.81 | 0.66-5.05 | 0.20 |
| 3 | 1,374 | 10 | 7.28 | 3.92-13.53 | 1.30 | 0.48-3.63 | 0.57 |
| 4 | 1,248 | 8 | 6.41 | 3.21-12.82 | 1.15 | 0. 39-3.35 | 0.78 |
| SNP | |||||||
| Sin SNP | 3,915 | 27 | 6.90 | 4.73 - 10.06 | 1 | ||
| Con SNP | 1,308 | 10 | 7.65 | 4.11 - 14.21 | 1.11 | 0.48 - 2.36 | 0.76 |
TI: Tasa de incidencia x 1,000 personas-día,
RTI: Razón de las tasas de incidencia.
IC 95%: 95% intervalo de confianza.
Tasas de incidencia acumuladas de alineación del arco inferior por tratamiento y presencia de polimorfismo.
| Persona-tiempo | Alineado (n) | TI | TI - IC 95% | RTI | RTI - IC 95% | ||
|---|---|---|---|---|---|---|---|
| Grupo | |||||||
| 1 | 1,860 | 9 | 4.84 | 2.52-9.30 | 1 | ||
| 2 | 1,467 | 10 | 6.82 | 3.67-12.67 | 1.41 | 0.51-3.92 | 0.46 |
| 3 | 1,653 | 10 | 6.05 | 3.26-11.24 | 1.25 | 0.46-3.48 | 0.63 |
| 4 | 1,253 | 7 | 5.59 | 2.67-11.72 | 1.15 | 0.37-3.48 | 0.77 |
| SNP | |||||||
| Sin SNP | 4,350 | 26 | 5.98 | 4.07-8.78 | 1 | ||
| Con SNP | 1,883 | 10 | 5.31 | 2.86-9.87 | 0.89 | 0.38-1.90 | 0.77 |
TI: Tasa de incidencia x 1,000 personas-día
RTI: Razón de las tasas de incidencia
95%, IC: 95% intervalo de confianza.
|
|
| Given that different patients may have different results in the treatment time, depending on the genetic composition they have, it is relevant to evaluate the interaction between the acceleration techniques and the genotype of patients. |
|
|
| Our results showed that the use of decortication and collagen matrices allowed a reduction in the total treatment time, while the presence of the allele 2 in the IL-1β had no effect. |
|
|
| Our findings contribute to have a clearer vision of the alternatives that can favor a shorter treatment time in orthodontics. |
| Dado que diferentes pacientes pueden tener diferentes resultados en el tiempo de tratamiento, dependiendo de la composición genética que tengan, es relevante evaluar la interacción entre las técnicas de aceleración y el genotipo de los pacientes. |
| Los resultados mostraron que el uso de decorticación y matrices de colágeno permitieron una reducción en el tiempo total de tratamiento, mientras que la presencia del alelo 2 en la IL-1β no tuvo efecto. |
| Los hallazgos contribuyen a tener una visión más clara de las alternativas que pueden favorecer un tiempo de tratamiento más corto en ortodoncia. |